The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Mitochondria‐targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants
Abstract
Friedreich Ataxia (FRDA), the most common inherited ataxia, arises from defective expression of the mitochondrial protein frataxin, which leads to increased mitochondrial oxidative damage. Therefore, antioxidants targeted to mitochondria should be particularly effective at slowing disease progression. To test this hypothesis, we compared the efficacy of mitochondria‐targeted and untargeted antioxidants derived from coenzyme Q 10 and from vitamin E at preventing cell death due to endogenous oxidative stress in cultured fibroblasts from FRDA patients in which glutathione synthesis was blocked. The mitochondria‐targeted antioxidant MitoQ was several hundredfold more potent than the untargeted analog idebenone. The mitochondria‐targeted antioxidant MitoVit E was 350‐fold more potent than the water soluble analog Trolox. This is the first demonstration that mitochondria‐targeted antioxidants prevent cell death that arises in response to endogenous oxidative damage. Targeted antioxidants may have therapeutic potential in FRDA and in other disorders involving mitochondrial oxidative damage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In other studies, the EC50 for MitoQ in cultured cells was <0.5 nM, and the protective effect then plateaued over several logs of concentration (Jauslin et al., 2003).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Jauslin et al., 2003
In the citing paper
“There is extensive in vitro evidence that the concentrations of MitoQ used here have no impact on mitochondrial functions, such as ATP production, membrane potential, or ROS production in cells or mitochondria, but do prevent mitochondrial oxidative damage under conditions that lead to oxidative stress (Kelso et al., 2001; Jauslin et al., 2003; Saretzki et al., 2003; Asin-Cayuelaa et al., 2004).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Jauslin et al., 2003
In the citing paper
“Mitochondrially-targeted coenzyme Q (MitoQ) or mitochondrially-targeted vitamin E (MitoVitE) have been shown to target mitochondrial dysfunction282,283.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [283]
In the citing paper
“Mitochondrial-targeted antioxidants protected Friedreich ataxia fibroblasts, in which glutathione synthesis was blocked, from oxidative stress (148)”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [148]
In the citing paper
“In glioma cells, astrocytes, and macrophages, Fpn associates with ceruloplasmin (Cp) (123, 148).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [148]
In the citing paper
“Inability to export iron may explain tissue iron accumulation.”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [148]
In the citing paper
“Adult Cp-knockout mice exhibited accumulation of iron in the cerebellum and brainstem that correlated with the development of deficits in coordination of movement (148).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [148]
In the citing paper
“GPI-anchored Cp was required for export of iron from astrocytes (148) (Table 4).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [148]
Citations
Cites
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786
Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
Self-citationRegulation of Mitochondrial Iron Accumulation by Yfh1p, a Putative Homolog of Frataxin
Babcock, M., de Silva, D., Oaks, R., Davis-Kaplan, S., Jiralerspong, S., Montermini, L., Pandolfo, M., & Kaplan, J. (1997) · Science · doi:10.1126/science.276.5319.1709 · Cited by 921
Puccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P., & Koenig, M. (2001) · Nature Genetics · doi:10.1038/84818 · Cited by 738
Delivery of bioactive molecules to mitochondria in vivo
Smith, R. A. J., Porteous, C. M., Gane, A. M., & Murphy, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931245100 · Cited by 725
Self-citationSelective targeting of an antioxidant to mitochondria
Smith, R. A. J., Porteous, C. M., Coulter, C. V., & Murphy, M. P. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00543.x · Cited by 466
Self-citationDrug delivery to mitochondria: the key to mitochondrial medicine
Murphy, M. P., & Smith, R. A. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00069-1 · Cited by 429
Self-citationSelective targeting of bioactive compounds to mitochondria
Murphy, M. P. (1997) · Trends in Biotechnology · doi:10.1016/s0167-7799(97)01068-8 · Cited by 366
Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia
Lodi, R., Cooper, J. A. D., Bradley, J. L., Manners, D. N., Styles, P., Taylor, D. J., & Schapira, A. H. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11492 · Cited by 352
Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue
Wilson, R. B., & Roof, D. M. (1997) · Nature Genetics · doi:10.1038/ng0897-352 · Cited by 345
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 356
Hyperglycemia-Induced Reactive Oxygen Species and Impaired Endothelial Progenitor Cell Function
Callaghan, M. J., Ceradini, D. J., & Gurtner, G. C. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1476 · Cited by 116
Mitochondrial DNA-Associated Leigh Syndrome and NARP
Thorburn, D. R., Rahman, J., & Rahman, S. (2014) · University of Washington, Seattle eBooks · Cited by 116
Mitochondria‐Targeted Antioxidants in the Treatment of Disease
Smith, R. A. J., Adlam, V. J., Blaikie, F. H., Manas, A. B., Porteous, C. M., James, A. M., Ross, M. F., Logan, A., Cochemé, H. M., Trnka, J., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.003 · Cited by 113
Self-citationNutraceutics and Delivery Systems
Shôji, Y., & Nakashima, H. (2004) · Journal of drug targeting · doi:10.1080/10611860400003817 · Cited by 114
Lifespan and mitochondrial control of neurodegeneration
Wright, A. F., Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Shu, X., Vlachantoni, D., McInnes, R. R., & Riemersma, R. A. (2004) · Nature Genetics · doi:10.1038/ng1448 · Cited by 111
Mitochondria-Targeted Antioxidants for Treatment of Hearing Loss: A Systematic Review
Fujimoto, C., & Yamasoba, T. (2019) · Antioxidants · doi:10.3390/antiox8040109 · Cited by 109
New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases
Scarian, E., Viola, C., Dragoni, F., Gerlando, R. D., Rizzo, B., Diamanti, L., Gagliardi, S., Bordoni, M., & Pansarasa, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052698 · Cited by 118
Cardiomyopathy of Friedreich Ataxia
Weidemann, F., Störk, S., Liu, D., Hu, K., Herrmann, S., Ertl, G., & Niemann, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12217 · Cited by 109
Vyas, P. M., Tomamichel, W. J., Pride, P. M., Babbey, C. M., Wang, Q., Mercier, J., Martin, E. M., & Payne, R. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr554 · Cited by 115
Hemigramicidin–TEMPO conjugates: Novel mitochondria-targeted anti-oxidants
Fink, M. P., Macias, C. A., Xiao, J., Tyurina, Y. Y., Jiang, J., Belikova, N. A., Delude, R. L., Greenberger, J. S., Kagan, V. E., & Wipf, P. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.05.019 · Cited by 107
Reddy, C. A., Venkateswarlu, S., Golakoti, T., Kanugula, A. K., Karnewar, S., Karthikraj, R., Nagarjuna, V., Prabhakar, S., Kuppusamy, P., Kotamraju, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089351 · Cited by 108
The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease
Camilleri, A., & Vassallo, N. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12264 · Cited by 106
Zang, Q. S., Sadek, H. A., Maass, D. L., Martinez, B., Ma, L., Kilgore, J. A., Williams, N. S., Frantz, D. E., Wigginton, J. G., Nwariaku, F. E., et al. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00203.2011 · Cited by 104
Friedreich's ataxia: Past, present and future
Marmolino, D. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.04.001 · Cited by 106
Abdelmegeed, M. A., Ha, S.-K., Choi, Y., Akbar, M. D., & Song, B. (2017) · Current Molecular Pharmacology · doi:10.2174/1874467208666150817111114 · Cited by 106
Complex I Dysfunction and Tolerance to Nitroglycerin
Esplugues, J. V., Rocha, M., Nuñez, C., Boscá, I., Ibiza, S., Herance, J. R., Ortega, Á., Serrador, J. M., D’Ocón, P., & Víctor, V. M. (2006) · Circulation Research · doi:10.1161/01.res.0000250430.62775.99 · Cited by 103
Understanding aging: revealing order out of chaos
Dufour, É., & Larsson, N. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.04.020 · Cited by 103
Mitochondria targeting drugs for neurodegenerative diseases—Design, mechanism and application
Xu, J., Du, W., Zhao, Y., Lim, K., Li, L., Zhang, C., & Li, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.001 · Cited by 101
Lowes, D. A., Wallace, C. A., Murphy, M. P., Webster, N. R., & Galley, H. F. (2009) · Free Radical Research · doi:10.1080/10715760902736275 · Cited by 100
Triphenylphosphonium (TPP)‐Based Antioxidants: A New Perspective on Antioxidant Design
Wang, J., Li, J. Q., Xiao, Y., Fu, B., & Qin, Z. (2020) · ChemMedChem · doi:10.1002/cmdc.201900695 · Cited by 103
Nuzzo, A. M., Camm, E. J., Sferruzzi-Perri, A. N., Ashmore, T. J., Yung, H. W., Cindrová‐Davies, T., Spiroski, A., Sutherland, M. R., Logan, A., Austin‐Williams, S., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.027 · Cited by 94
Frataxin, Iron–Sulfur Clusters, Heme, ROS, and Aging
Napoli, E., Taroni, F., & Cortopassi, G. A. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.506 · Cited by 96
Flaviviridae Viruses and Oxidative Stress: Implications for Viral Pathogenesis
Zhang, Z., Rong, L., & Li, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/1409582 · Cited by 95
MitoQ Loaded Chitosan-Hyaluronan Composite Membranes for Wound Healing
Tamer, T. M., Collins, M. N., Valachová, K., Hassan, M. A., Omer, A. M., Eldin, M. S. M., Švík, K., Jurčík, R., Ondruška, Ľ., Biró, C., et al. (2018) · Materials · doi:10.3390/ma11040569 · Cited by 94
Gibson, B. W. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.11.013 · Cited by 93
Cationic antioxidants as a powerful tool against mitochondrial oxidative stress
Skulachev, V. P. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.063 · Cited by 91
Navarro, A., & Boveris, A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.05.002 · Cited by 88
Schroeder, P., Gremmel, T., Berneburg, M., & Krutmann, J. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.57 · Cited by 85
Víctor, V. M., & Rocha, M. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780363077 · Cited by 85
Animal and cellular models of Friedreich ataxia
Perdomini, M., Hick, A., Puccio, H. M., & Pook, M. A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12219 · Cited by 92
Bottani, E., Lamperti, C., Prigione, A., Tiranti, V., Persico, N., & Brunetti, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111083 · Cited by 89
Abnormal Mitochondrial Dynamics—A Novel Therapeutic Target for Alzheimer's Disease?
Su, B., Wang, X., Bonda, D., Perry, G. L., Smith, M. A., & Zhu, X. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8095-7 · Cited by 85
Targeting mitochondrial dysfunction in neurodegenerative disease: Part II
Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 83
Brown, S. E., Ross, M. F., Sanjuán-Pla, A., Manas, A. B., Smith, R. A. J., & Murphy, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.02.033 · Cited by 81
Self-citationSkulachev, V. P. (2005) · IUBMB Life · doi:10.1080/15216540500092161 · Cited by 80
Mitochondrial medicine for neurodegenerative diseases
Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82
Friedreich's Ataxia: From Disease Mechanisms to Therapeutic Interventions
Lodi, R., Tonon, C., Calabrese, V., & Schapira, A. H. V. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.438 · Cited by 79
Mitochondria-targeted redox probes as tools in the study of oxidative damage and ageing
James, A. M., Cochemé, H. M., & Murphy, M. P. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.03.026 · Cited by 77
Dibrova, D. V., Cherepanov, D. A., Galperin, M. Y., Skulachev, V. P., & Mulkidjanian, A. Y. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2013.07.006 · Cited by 77
Siler‐Marsiglio, K. I., Pan, Q., Paiva, M., Madorsky, I., Khurana, N. C., & Heaton, M. B. (2005) · Brain Research · doi:10.1016/j.brainres.2005.06.030 · Cited by 75
Mao, Z., Choo, Y. S., & Lesort, M. J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04686.x · Cited by 75
Saberi, M., Zhang, X., & Mobasheri, A. (2021) · GeroScience · doi:10.1007/s11357-021-00341-1 · Cited by 76
Mizuguchi, Y., Chen, J., Seshan, S. V., Poppas, D. P., Szeto, H. H., & Felsen, D. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00395.2007 · Cited by 72
Friedreich ataxia?update on pathogenesis and possible therapies
Voncken, M., Ioannou, P. A., & Delatycki, M. B. (2004) · Neurogenetics · doi:10.1007/s10048-003-0170-z · Cited by 70
Koju, N., Taleb, A., Zhou, J., Ge, L., Yang, J., Cao, X., Lei, H., & Ding, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.128 · Cited by 72
Mitochondrial-targeted penetrating peptide delivery for cancer therapy
Wu, J., Li, J., Wang, H., & Liu, C.-B. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1517750 · Cited by 67
Severina, I. I., Severin, F. F., Korshunova, G. A., Sumbatyan, N. V., Ilyasova, T. M., Simonyan, R. A., Rogov, A. G., Trendeleva, T. A., Zvyagilskaya, R. A., Dugina, V. B., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.043 · Cited by 68
Bhatti, G. K., Gupta, A., Pahwa, P., Khullar, N., Singh, S., Navik, U., Kumar, S., Mastana, S. S., Reddy, A. P., Reddy, P. H., et al. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.05.002 · Cited by 66
Aldosterone and cardiovascular disease: the heart of the matter
He, B. J., & Anderson, M. E. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.09.004 · Cited by 66
Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer’s disease
Yoo, S., Park, J., Kim, S., & Jung, Y. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.274 · Cited by 65
Functional and molecular characterization of the frataxin homolog from Arabidopsis thaliana,
Busi, M. V., Zabaleta, E. J., Araya, A., & Gomez‐Casati, D. F. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.003 · Cited by 64
Dynamics, stability and iron‐binding activity of frataxin clinical mutants
Correia, A. R., Pastore, C., Adinolfi, S., Pastore, A., & Gomes, C. M. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06512.x · Cited by 63
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I
Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652489 · Cited by 64
Mitochondrial Transfer as a Therapeutic Strategy Against Ischemic Stroke
Chen, W., Huang, J., Hu, Y., Khoshnam, S. E., & Sarkaki, A. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00828-7 · Cited by 62
Polyzos, A. A., Holt, A., Brown, C., Cosme, C. G., Wipf, P., Gómez-Marín, À., Castro, M. D. R., Ayala‐Peña, S., & McMurray, C. T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw051 · Cited by 65
Gómez-Sebastián, S., Giménez-Cassina, A., Díaz‐Nido, J., Lim, F., & Wade‐Martins, R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300021 · Cited by 62
Estrogen Prevents Oxidative Damage to the Mitochondria in Friedreich's Ataxia Skin Fibroblasts
Richardson, T. E., Yu, A. E., Wen, Y., Yang, S., & Simpkins, J. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034600 · Cited by 60
Clark, E. M., Johnson, J., Dong, Y., Mercado‐Ayón, E., Warren, N., Zhai, M., McMillan, E., Salovin, A., Lin, H., & Lynch, D. R. (2018) · Neuronal Signaling · doi:10.1042/ns20180060 · Cited by 64
Wang, X., Peng, H., Yang, L., You, F., Teng, F., Tang, A., Zhang, F., & Li, X. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20884b · Cited by 60
Krzywanski, D. M., Moellering, D. R., Fetterman, J. L., Dunham‐Snary, K. J., Sammy, M. J., & Ballinger, S. W. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.95 · Cited by 60
Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Smeitink, J. A. M., van den Heuvel, L., Koopman, W. J. H., Nijtmans, L. G. J., Ugalde, C., & Willems, P. H. G. M. (2004) · Current Neurovascular Research · doi:10.2174/1567202043480224 · Cited by 60
Burelle, Y., Khairallah, M., Ascah, A., Allen, B. G., Deschepper, C. F., Petrof, B. J., & Rosiers, C. D. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.09.004 · Cited by 61
Mukherjee, T. K., Mishra, A. K., Mukhopadhyay, S., & Hoidal, J. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1835 · Cited by 56
Novel HPMA Copolymer-Bound Constructs for Combined Tumor and Mitochondrial Targeting
Cuchelkar, V., Kopečková, P., & Kopec̆ek, J. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800019g · Cited by 57
Vlachantoni, D., Bramall, A. N., Murphy, M. P., Taylor, R. W., Shu, X., TULLOCH, B. R., Veen, T. V., Turnbull, D. M., McInnes, R. R., & Wright, A. F. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq467 · Cited by 53
Delivery of drugs and macromolecules to mitochondria☆
Mukhopadhyay, A., & Weiner, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.004 · Cited by 55
Mitochondrial Dysfunction in Stroke: Implications of Stem Cell Therapy
Sarmah, D., Kaur, H., Saraf, J., Vats, K., Pravalika, K., Wanve, M., Kalia, K., Borah, A., Kumar, A., Wang, X., et al. (2018) · Translational Stroke Research · doi:10.1007/s12975-018-0642-y · Cited by 55
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P. (2008) · Wiley eBooks · doi:10.1002/9780470372531.ch25 · Cited by 55
Fairley, L. H., Das, S., Dharwal, V., Amorim, N. M. L., Hegarty, K. J., Wadhwa, R., Mounika, G., & Hansbro, P. M. (2023) · Antioxidants · doi:10.3390/antiox12040973 · Cited by 60
Timm, K. N., Perera, C., Ball, V., Henry, J. A., Miller, J. J. J. J., Kerr, M. J., West, J. A., Sharma, E., Broxholme, J., Logan, A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01440-z · Cited by 51
Oxidative Stress Treatment for Clinical Trials in Neurodegenerative Diseases
Ienco, E. C., LoGerfo, A., Carlesi, C., Orsucci, D., Ricci, G., Mancuso, M., & Siciliano, G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110164 · Cited by 56
Ghelli, A. M., Porcelli, A. M., Zanna, C., Martinuzzi, A., Carelli, V., & Rugolo, M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0880 · Cited by 53
Diers, A. R., Higdon, A. N., Ricart, K. C., Johnson, M. S., Agarwal, A., Kalyanaraman, B., Landar, A. L., & Darley-Usmar, V. M. (2009) · Biochemical Journal · doi:10.1042/bj20091293 · Cited by 53
Mitochondrial oxidative stress and mammalian healthspan
Wanagat, J., Dai, D., & Rabinovitch, P. S. (2010) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2010.06.002 · Cited by 52
Pharmacological significance of MitoQ in ameliorating mitochondria-related diseases
Sulaimon, L. A., Afolabi, L. O., Adisa, R. A., Ayankojo, A. G., Afolabi, M. O., Adewolu, A. M., & Wan, X. (2022) · Advances in Redox Research · doi:10.1016/j.arres.2022.100037 · Cited by 50
Transition metals and mitochondrial metabolism in the heart
Rines, A. K., & Ardehali, H. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.05.014 · Cited by 51
Kinetic Analysis of Permeation of Mitochondria-Targeted Antioxidants Across Bilayer Lipid Membranes
Rokitskaya, T. I., Klishin, S. S., Severina, I. I., Skulachev, V. P., & Antonenko, Y. N. (2008) · The Journal of Membrane Biology · doi:10.1007/s00232-008-9124-6 · Cited by 50
Mao, G., Kraus, G. A., Kim, I., Spurlock, M. E., Bailey, T. B., Zhang, Q., & Beitz, D. C. (2010) · The Journal of Nutrition · doi:10.3945/jn.110.121715 · Cited by 48
Mitochondrial bioenergetics and redox dysfunctions in hypercholesterolemia and atherosclerosis
Oliveira, H. C. F., & Vercesi, A. E. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100840 · Cited by 49
Serviddio, G., Romano, A. D., Cassano, T., Bellanti, F., Altomare, E., & Vendemiale, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796904740 · Cited by 45
Synthesis of triphenylphosphonium vitamin E derivatives as mitochondria-targeted antioxidants
Jameson, V. J. A., Cochemé, H. M., Logan, A., Hanton, L. R., Smith, R. A. J., & Murphy, M. P. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.09.014 · Cited by 47
Self-citationPátková, J., Anděl, M., & Trnka, J. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358709 · Cited by 46
Mitochondria: Mitochondrial OXPHOS (dys) function ex vivo – The use of primary fibroblasts
Saada, A. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.010 · Cited by 46
Whiteman, M., Spencer, J. P. E., Szeto, H. H., & Armstrong, J. S. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1879 · Cited by 44
Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
Moreira, P. I., Cardoso, S. M., Pereira, C., Santos, M. S., & Oliveira, C. R. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824651 · Cited by 44
Fernández‐Ayala, D. J. M., López‐Lluch, G., García-Valdés, M., Arroyo, A., & Navas, P. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.10.009 · Cited by 44
Is defective electron transport at the hub of aging?
Maklashina, E., & Ackrell, B. A. C. (2003) · Aging Cell · doi:10.1111/j.1474-9728.2003.00078.x · Cited by 43
Synthesis and properties of fluorescence probe for detection of peroxides in mitochondria
Shioji, K., Oyama, Y., Okuma, K., & Nakagawa, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.017 · Cited by 42
Rapamycin reduces oxidative stress in frataxin-deficient yeast cells
Marobbio, C. M. T., Pisano, I., Porcelli, V., Lasorsa, F. M., & Palmieri, L. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.07.001 · Cited by 43
Kim, A., Murphy, M., & Oberley, T. (2005) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2004.10.030 · Cited by 46
Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells
Saito, Y., Fukuhara, A., Nishio, K., Hayakawa, M., Ogawa, Y., Sakamoto, H., Fujii, K., Yoshida, Y., & Niki, E. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2008.04.005 · Cited by 42
Lü, C., Zhang, D., Whiteman, M., & Armstrong, J. S. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1865 · Cited by 40
Idebenone in Friedreich's ataxia
Tonon, C., & Lodi, R. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.13.2327 · Cited by 43
Choo, Y. S., Mao, Z., Johnson, G. V. W., & Lesort, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.065 · Cited by 42
Fleming, J., Spinoulas, A., Zheng, M., Cunningham, S. C., Ginn, S. L., McQuilty, R. C., Rowe, P. B., & Alexander, I. E. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.947 · Cited by 42
Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance
Cui, H., Huan, M., Ye, W., Liu, D., Teng, Z., Mei, Q., & Zhou, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01016 · Cited by 39
Napoli, E., Morin, D., Bernhardt, R., Buckpitt, A. R., & Cortopassi, G. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.04.001 · Cited by 39
Bandaru, L. J. M., Ayyalasomayajula, N., Murumulla, L., & Challa, S. (2022) · BioMetals · doi:10.1007/s10534-021-00360-7 · Cited by 39
Targeting Mitochondria as Therapeutic Strategy for Metabolic Disorders
Sorriento, D., Pascale, A. V., Finelli, R., Carillo, A. L., Annunziata, R., Trimarco, B., & Iaccarino, G. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/604685 · Cited by 39
RetractedRedox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Kovacic, P., & Somanathan, R. (2012) · Current Neuropharmacology · doi:10.2174/157015912804143487 · Cited by 38
Metadata
- Authors
- Jauslin, M. L., Meier, T., Smith, R. A. J., & Murphy, P. M.
- Affiliations
- Geotech Co., Ltd. (Japan) (JP)
- University of Otago (NZ)
- MRC-Dunn Human Nutrition Unit Cambridge CB2 2XY United Kingdom
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-08-15
- Volume
- 17
- Issue
- 13
- Pages
- 1-10
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2154919554
- Cited by
- 358
- References
- 21
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 8 · 2023: 14 · 2022: 11 · 2021: 7 · 2020: 11 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 11 · 2015: 14 · 2014: 17 · 2013: 19 · 2012: 21
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission (QLRT-CT-1999-00584)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- Friedreich's ataxia, mitochondria-targeted antioxidants, oxidative stress, frataxin, mitochondrial oxidative damage, MitoQ, idebenone, Trolox, vitamin E, coenzyme Q10, glutathione deficiency, fibroblasts, cell death, mitochondrial disease therapy
- MeSH terms
- Antioxidants, Fibroblasts, Friedreich Ataxia, Humans, Mitochondria, Models, Biological, Organophosphorus Compounds, Ubiquinone, Vitamin E, Benzoquinones, Drug Delivery Systems, Cell Death, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
